was well tolerated. The PARADIGM-HF study has an important clinical significance and would change the pattern of HF treatment in the future. 【Key words】 PARADIGM-HF trial; Chronic heart failure with reduced ejection fraction; Angiotensin receptor-neprilysin inhibitor 2014 年 8 月 30 日在欧洲心脏...
钠尿肽是尼泊尔霉素的底物,因此,B型钠尿肽(BNP)的浓度随着尼泊尔霉素的抑制而升高。因此,在沙库巴曲/缬沙坦治疗的患者中测量bnp的临床有效性受到质疑,并且推荐使用n末端pro-b型钠尿肽(nt-propnp)。 Objectives The purpose of this study was...
Zannad F, EMPHASIS-HF Study Group. N Engl J Med2011;364:11–21 4. Konstam MA, HEAAL Investigators. Lancet 2009;374:1840– 1848 PARADIGM-HF试验的设计 单盲导入期 双盲期 ® 诺欣妥® 诺欣妥 200 mg BID(n=4187) 依那普利 10 mg,BID 100 mg 200 mg (1:1 随机分配) BID BID 2周 ...
The PARADIGM-HF study is so far the largest study in heart failure, which included more than 8000 patients with symptomatic HFrEF. Due to superiority of the combined angiotensin receptor-neprilysin-inhibitor LCZ696 the PARADIGM-HF study was terminated early after a median follow-up of 27 months....
Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF studySacubitril/valsartanEnalaprilAngioedemaSafetyHFrEFHeart failureBackground: PARADIGM-HF demonstrated significant clinical benefits for sacubitril/valsartan (LCZ696, an angiotensin receptor ...
In April, Novartis announced theearly closure of PARADIGM-HFafter it met the primary composite endpoint — CV death or first incidence of HF-related hospitalization — and also showed a significant reduction in the risk for CV death. At the end of the study, the p...
Introduction:\nIn the PARADIGM-HF study, sacubitril/valsartan demonstrated a 16% decrease in all-cause mortality and a 21% decrease in heart failure hospitalization. Cost and concern for a higher risk of side effects especially among old... L Gilstrap,R Zipkin,J Barnes,... - 《Circulation...
The purpose of this study was to compare outcomes (and the effect of sacubitril/valsartan) according to etiology in the PARADIGM-HF (Prospective comparison of angiotensin-receptor-neprilysin inhibitor [ARNI] with angiotensin-converting-enzyme inhibitor [ACEI] to Determine Impact on Global Mortality an...
A new class of drugs for systolic heart failure: the PARADIGM-HF study The PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) found a combination drug containing sacubitril (a neprilysin inhibitor) and valsartan (an...
However, few of these patients discontinued study drug because of hypotension. There was no interaction between age and treat- ment on the rate of hypotension or any of the other adverse events leading to treatment discontinuation. Discussion A larger number of patients with a b...